搜索优化
Rewards
English
搜索
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
房地产
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
过去 7 天
时间不限
过去 1 小时
过去 24 小时
过去 30 天
按时间排序
按相关度排序
19 小时
on MSN
India Launches First-Ever Cancer Genomics Repository; To Provide Better Awareness ...
Foundation has launched the country’s first comprehensive cancer genomics repository, to improve the understanding of genetic ...
Zacks.com on MSN
3 天
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ Drugs
This week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...
MM&M
3 天
Rx Rundown: MaxCyte, Roche, and more
Kajeet and Avery Telehealth announced a strategic partnership. The FDA has approved Apple’s sleep apnea detection feature.
4 天
Breastfeeding supports healthy infant microbiome, lowering asthma risk
Breastfeeding through the first year of infants' lives can lower their risk of asthma by colonizing their bodies with a ...
4 天
Kisqali wins FDA nod for breast cancer treatment: Dosage, effectiveness and side effects of ...
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...
NBC Connecticut
4 天
US ranks last in health care compared with nine other high-income countries, report finds
People in the U.S. die the youngest and experience the most avoidable deaths, despite spending much more on health care. NBC ...
Medscape
4 天
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...
biopharma-reporter
4 天
Novartis’ Kisqali receives FDA approval to reduce the risk of breast cancer recurrence
Novartis announced this week that the FDA has approved ribociclib (marketed as Kisqali) for the treatment of people with ...
4 天
Black women are more likely than white women to die of all types of breast cancer
Black women are more likely than white women to die from even the most treatable types of breast cancer, a study published ...
Pharmabiz
4 天
Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with ...
Novartis’ Kisqali receives US FDA approval to reduce risk of recurrence in people with HR+/HER2- early breast cancer: Basel Thursday, September 19, 2024, 13:00 Hrs [IST] Novarti ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈